Výsledky vyhledávání - "Raymond L. H. Lam"

Missing Data Imputation With Baseline Information in Longitudinal Clinical Trials

Autor: Gregory T. Golm, Lei Xu, Zachary Zimmer, Susan Huyck, Raymond L. H. Lam, Yilong Zhang

Publikováno v: Statistics in Biopharmaceutical Research. 14:242-248

In longitudinal clinical trials, missing data are inevitable despite every effort made to retain patients in the trial. Missing data cause difficulty in the estimation and interpretation of the tre...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::6b8420d98b493e365bf56ae0cb41767e
https://doi.org/10.1080/19466315.2020.1845234

Zobrazit plný text záznamu

A randomized clinical trial of the efficacy and safety of sitagliptin as initial oral therapy in youth with type 2 diabetes

Autor: Yulia Samoilova, Gregory T. Golm, Keith D. Kaufman, Martina Zilli, Yilong Zhang, Chandan Saha, Naim Shehadeh, Samuel S. Engel, Ron S. Newfield, Carmen A. Rosario, Asma Deeb, Lynn W. Scherer, R. Ravi Shankar, Raymond L. H. Lam, Muhammad Yazid Jalaludin, Philip Zeitler, Raymundo Garcia

Publikováno v: Pediatric diabetesREFERENCES. 23(2)

OBJECTIVE To assess the efficacy and safety of DPP-4 inhibition with sitagliptin in youth with type 2 diabetes (T2D). STUDY DESIGN This was a 54-week, double-blind, randomized, controlled clinical trial evaluating the safety and efficacy of DPP-4 inh

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::71bd003177464486515b02e17e291077
https://pubmed.ncbi.nlm.nih.gov/34779087

Zobrazit plný text záznamu

Efficacy and safety of the addition of sitagliptin to treatment of youth with type 2 diabetes and inadequate glycemic control on metformin without or with insulin

Autor: Keith D. Kaufman, Asma Deeb, Gregory T. Golm, Philip Zeitler, Martina Zilli, Carmen A. Rosario, Ron S. Newfield, R. Ravi Shankar, Lynn W. Scherer, Raymundo Garcia, Muhammad Yazid Jalaludin, Yulia Samoilova, Samuel S. Engel, Raymond L. H. Lam, Naim Shehadeh, Chandan Saha, Yilong Zhang

Publikováno v: Pediatric diabetesREFERENCES. 23(2)

Objective To assess the efficacy and safety of sitagliptin in youth with type 2 diabetes (T2D) inadequately controlled with metformin ± insulin. Study design Data were pooled from two 54-week, double-blind, randomized, placebo-controlled studies of

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0d08f661c718e140b12d4ae6b6d10d53
https://pubmed.ncbi.nlm.nih.gov/34779103

Zobrazit plný text záznamu

A randomized clinical trial of the efficacy and safety of sitagliptin compared with dapagliflozin in patients with type 2 diabetes mellitus and mild renal insufficiency: The CompoSIT‐R study

Autor: Jerry D. Morgan, Zachary Zimmer, Annaswamy Raji, Russell S. Scott, Samuel S. Engel, Raymond L. H. Lam, Edward A. O'Neill, Keith D. Kaufman

Publikováno v: Diabetes, Obesity & Metabolism

Aim To compare the efficacy and safety of the dipeptidyl peptidase‐4 inhibitor sitagliptin with the sodium‐glucose transporter‐2 inhibitor dapagliflozin in patients with type 2 diabetes and mild renal insufficiency. Materials and Methods Patien

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a5813d5152ad9f3046123abcb26d8467
http://europepmc.org/articles/PMC6283039

Zobrazit plný text záznamu

Efficacy and safety of MK-1293 insulin glargine compared with originator insulin glargine (Lantus) in type 1 diabetes: A randomized, open-label clinical trial

Autor: Raymond L. H. Lam, Julio Rosenstock, Wendy L. Carofano, Roy Eldor, Gregory T. Golm, Philip Home, Baptist Gallwitz, Michael C. Marcos, Priscilla Hollander, Michael F. Crutchlow

Publikováno v: Diabetes, Obesity and Metabolism. 20:2220-2228

Aim To compare the efficacy and safety of MK-1293 insulin glargine (Mk-Gla; 100 U/mL) with originator insulin glargine, Lantus (Sa-Gla), in people with type 1 diabetes mellitus (T1DM). Materials and methods This phase 3, randomized, active-controlled

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f58ff53d3128cdeebf56d91c4bad422c
https://doi.org/10.1111/dom.13354

Zobrazit plný text záznamu

Phase I Trial of the Human Double Minute 2 Inhibitor MK-8242 in Patients With Advanced Solid Tumors

Autor: Clayton D. Knox, Amit Mahipal, Heather Hirsch, Neeta Somaiah, Andrew J. Wagner, Amy O. Johnson-Levonas, Giuseppe Russo, David S. Hong, Raymond L. H. Lam, Shelonitda Rose, Udai Banerji, Craig Fancourt, Amy Meister

Publikováno v: Journal of Clinical Oncology. 35:1304-1311

Purpose To evaluate MK-8242 in patients with wild-type TP53 advanced solid tumors. Patients and Methods MK-8242 was administered orally twice a day on days 1 to 7 in 21-day cycles. The recommended phase II dose (RP2D) was determined on the basis of s

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::77d77afcdf8e2fbafe41e84e2fec7e76
https://doi.org/10.1200/jco.2016.70.7117

Zobrazit plný text záznamu

1149-P: A1C Goal Attainment after Metformin (MET) Uptitration With and Without Sitagliptin (SITA): Impact of Baseline and Target A1C

Autor: Raymond L. H. Lam, Edward A. O'Neill, Keith D. Kaufman, Samuel S. Engel, J. Lin, Michael F. Crutchlow

Publikováno v: Diabetes. 68

MET is generally recommended as the initial AHA for T2D, but many patients do not achieve glycemic goal at an initial, sub-maximal dose (500-1000 mg/day) and should intensify therapy. Typically, MET dose is first maximized, followed by addition of a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::76d4316ee7cb30f25cc14619a7cbfadb
https://doi.org/10.2337/db19-1149-p

Zobrazit plný text záznamu

1188-P: Glycemic Efficacy of Sitagliptin in East Asian Populations: A Pooled Analysis

Autor: Ye Zhang, Samuel S. Engel, Jongho Ahn, Annpey Pong, Raymond L. H. Lam, Claudio D. Gonzalez, J. Conceição, Shigeru Tokita, Ruya Zhang

Publikováno v: Diabetes. 68

The efficacy/safety of sitagliptin (SITA) has been studied in global populations. This post hoc pooled analysis of 20 placebo (PBO)-controlled studies reports data collected specifically in East Asian populations (EAP). Results were summarized for ov

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::6913ddd4263887ed8cefb25689776023
https://doi.org/10.2337/db19-1188-p

Zobrazit plný text záznamu

Double-blind, randomized clinical trial assessing the efficacy and safety of early initiation of sitagliptin during metformin uptitration in the treatment of patients with type 2 diabetes: The CompoSIT-M study

Autor: Raymond L. H. Lam, Keith D. Kaufman, Hideo Makimura, Catherine Ntabadde, Samuel S. Engel, Zachary Zimmer, Guillermo Amorin, Carol Iredale, Edward A. O'Neill, Juan P. Frias, Michael F. Crutchlow

Publikováno v: Diabetes, Obesity & Metabolism

AIMS To characterize the glycaemic efficacy and safety of initiation of the dipeptidyl peptidase-4 inhibitor sitagliptin during metformin dose escalation in people with type 2 diabetes (T2D) not at glycated haemoglobin (HbA1c) goal on a sub-maximal d

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::190aca559cbaf737640d8718b589e92f
https://pubmed.ncbi.nlm.nih.gov/30609212

Zobrazit plný text záznamu

Safety and Efficacy of Sitagliptin (SITA) Compared with Dapagliflozin (DAPA) in Subjects with T2D, Mild Renal Impairment, and Inadequate Glycemic Control on Metformin (MET) ± a Sulfonylurea (SU)

Autor: Zachary Zimmer, Annaswamy Raji, Edward A. O'Neill, Keith D. Kaufman, Jerry D. Morgan, Raymond L. H. Lam, Russell S. Scott, Samuel S. Engel

Publikováno v: Diabetes. 67

While choice of AHAs may be modified in patients with T2D and moderate or severe renal insufficiency, this is generally not the case in patients with mild renal insufficiency. Clinical trial data focused on this population, which represents ∼40% of

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::006c665c2089e442df027bf12cae09bd
https://doi.org/10.2337/db18-1142-p

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání